Two molecules -vascular endothelial growth factor involved in new vessels formation and survivin -antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapies the aim of the study was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival. material and methods. Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival. Results. Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor-and survivin-negative tumors. conclusions. It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.
Gastric carcinoma is one of the most common malignancies in the world. Despite the great progress in its early detection and therapy the prognosis is still poor with a 5-year survival rate of 20-25% (1) . The only potentially curative treatment for locally advanced gastric carcinoma is complete surgical resection, now supplied by modern minimally invasive techniques. Since lymph nodes metastases are common event that negatively influence prognosis, adjuvant and neoadjuvant therapies should be considered as a therapeutic option (1) . Most recently many novel targeted therapies are introduced like cell cycle inhibitors, apoptosis promoters, antiangiogenic agents, matrix metalloproteinases inhibitors etc. They require detailed understanding of biology of the tumor, especially mechanisms in-volved in invasiveness and metastases formation (2, 3) .
Vascular endothelial growth factor (VEGF) is a protein secreted by almost all tumors that influences endothelium and promotes proliferation of new vessels by binding specific receptors (Flt-1 and KDR). Current reports proved that over-expression of VEGF in malignant tumors are associated with tumor growth, metastasis and worse prognosis (3, 4) . Antiangiogenic therapy has been introduced in some digestive tract malignancies, mostly in colorectal carcinomas, but in the stomach it is still experimental (5) .
Among intracellular apoptosis inhibitors, survivin is the most important protein in the light of diagnostics and therapy. Apart from hampering apoptosis, survivin plays role in proliferation. Over-production of survivin and its mRNA has been observed in many malignant tumors including carcinomas of the lung, breast, stomach, colon and ovary as well as melanoma and lymphomas. It is associated with worse therapy results, higher risk of recurrences and resistance to chemotherapy (2, 6) . Since apoptosis inhibitors are present mainly in cancerous cells they are excellent goal for anti-neoplastic therapy.
The aim of the present study was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.
MATERIAL AND METHODS
The study was conducted on 41 patients with gastric carcinoma admitted to the 2 nd Department of General Surgery, Medical University in Lublin. They were treated with total or sub-total gastrectomy with at least D2 lymphadenectomy. The study group consisted of 11 females (26.83%) and 30 males (73.17%). The age of the patients ranged from 23 to 73 years (mean 61,12; median 64 years). The preoperative staging of the tumor was assessed based on: physical examination, gastroscopy, ultrasound examination, chest radiogram and in some cases computed tomography or endoscopic ultrasonography. Local invasion was evaluated during intraoperative assessment and subsequently supported by pathological examination. The surgical specimens were fixed in 10% buffered formalin. The samples were taken from the tumor and from normal-appearing wall of the stomach and then divided into 3-7 slides. In every case the proximal and distal resection margins and all lymph nodes were examined. The sections were routinely processed, embedded in paraffin blocks and stained with hematoxylin and eosin, mucicarmine, PAS and alcian blue, high iron diamine and Warthin-Starry methods. Evaluation of pathologic stage of the disease was based on the TNM system and the histological subtype of the carcinoma on the World Health Organization's criteria and Lauren classification (7) .
Immunohistochemical study was performed on 4-µm sections from one, representative paraffin block from each primary gastric tumor. Before the main reaction with survivin antibody was performed, antigen retrieval technique was applied and slices were pretreated in citrate buffer (0.01 M, pH 6.0) in a microwave oven (3x for 5 min). The slides for VEGF were pretreated by submerging in Target Retrieval Solution (pH 9.0; Dako, Denmark) and then placing in water at 95 o C for 20 minutes. For all antigens the endogenous peroxidase activity was blocked by 3% hydrogen peroxide solution for 5 min at the room temperature. The samples for survivin detection were then washed with TBS and 0.1% Tween20 solution three times for 5 minutes and afterwards washed with horse serum for 20 minutes. Next step was to use the primary antibody -monoclonal mouse antibody against human survivin (clone 12C4, Dako) in dilution 1:25 for 60 minutes. The slides were then washed 3 times for 5 minutes with TBS and incubated with ImmPress TM Universal Re-agent/Peroxidase (Vector Laboratories, USA) for 30 minutes. On the other hand, VEGF samples, after washing, were incubated with monoclonal mouse antibody against human VEGF (clone VG1, Dako) in dilution 1:20 for 60 minutes and then with complex DakoEnvision + /HRP, Mouse (Dako). All incubations were performed at room temperature and TBS was used every time the slides were washed. The specific immune reactions were visualized by 3',3-diaminobenzidine tetrahydrochloride (DAB) (Dako) for about 2 minutes in room temperature. Sections were than counterstained with Mayer's haematoxylin. Normal colonic mucosa was applied as a positive control. Slides treated in the same way, but with replacement of primary antibodies, were used as negative controls. Immunohistochemical reaction was evaluated by light microscope (Olympus BX45; Japan) equipped with eye grid. Percentage of positively-stained cells and the type of reaction (nuclear or cytoplasmic reaction) of each category were calculated in approximately 1000 cells of the some type in randomly selected areas using magnification 200x (4-7 fields).
Statistical differences between variables were evaluated using t-Student test or U Mann-Whitney and one-way analysis of variance was done using Kruskal-Wallis ANOVA. The quality parameters were analyzed by χ 2 and Fisher χ 2 test. Survival rates were calculated using Cox, χ 2 and log-rank tests. P values less than 0.05 were considered significant. Data were analysed by STATISTICA 5.0 on IBM compatible computer.
RESULTS
Positive immunohistochemical reaction for VEGF and survivin was revealed in 24 (58.53%) and 30 gastric carcinomas (73.17%), respectively. For VEGF the reaction was exclusively cytoplasic ( fig. 1A) , whereas for surviving both cytoplasmic and nuclear ( fig. 1B) .
VEGF-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases ( Table  1 ). The differences between other evaluated features, i.e., depth of infiltration and histological subtypes according to WHO and Lauren classifications were not significant.
No statistically significant differences were noted between survivin-positive and -negative cases and depth of stomach wall infiltration, regional lymph nodes status as well as histo- logical subtypes of carcinoma (tab. 2). However, distant metastases were statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reaction between less and more advanced cases almost reach statistical significance.
The only factors significantly influenced 1, 2 and 3-year survival in patients with gastric carcinoma were VEGF and surviving status. (-), (+) -ujemna i dodatnia reakcja immunohistochemiczna u pacjentów z gruczolakorakiem żołądka; ocena stopnia zaawansowania zgodnie z klasyfikacją pTNM (7) / negative and positive immunochistochemical reaction in gastric adenocarcinoma; staging according to pTNM (7); p -poziom istotności statystycznej / level of significance lignancies including gastric, pulmonary, esophageal, breast, colon, hepatic, pancreatic, urothelial, nasopharyngeal, uterine and ovarian carcinomas. The obtained data suggests that expression of both of these factors has a negative influence on prognosis (3, 6, 8) .
In the presented study, the role of both molecules was assessed according to their influence on the survival rate of patients with gastric adenocarcinoma. In the study group, VEGF was detected in 24 patients (58.53%) and survivn in 30 out of 41 cases (73.17%). Similar VEGF rate was obtain in other reports -Li et al. (6) detected VEGF in 76% and Choi et al. (9) in 62% of patients. Like in our study lack of statistically significant differences between survivn and VEGF status and age or histological type of the tumor was revealed in esophageal, colonic and nasopharyngeal carcinomas (10, 11) . Statistically significant connection was found between survivin expression and distant metastasis and between VEGF and the nodal and distal metastasis. Other studies report resembling data. Lu et al. (12) described significantly lower apoptotic index and co-expression of factors regulating apoptosis like p53 and bcl-2 in tumors secreting survivin. VEGF and its receptor VEGFR-3 were researched by others and proven to have connection with lymph node and distant metastasis in 91 patients (13) . In addition, significantly lower survival rate was observed in patients with higher VEGF expression. Sun et al. (4) found association between expression of survivin and VEGF and lymph node metastasis, pT and staging according to TNM UICC.
Connection between survivin expression and distant metastasis was also noted.
In the following part of our research, the results were compared with the staging according to TNM-UICC classification. There was a strong connection between VEGF immunostaining and the advanced stages of the tumor (p<0.05) and close to statistical significance in case of survivin immunostaining (p=0.065). Majority of studies also reports connection between the stage and VEGF immunostaining (14) . Similar data pertains not only to gastric malignancy (15) but also to esophageal (16) and colonic cancers (17) . Song et al. (15) indicated that presence of VEGF in tumor cells has a strong connection with metastasis to regional lymph nodes and the stage according to TNM UICC classification.
In our study, survivin immunostaining was compared to the mean survival time and it was 17.05 months compared to 32.55 months in patients with negative reaction for surviving (p<0.05). Similar results were obtained comparing VEGF, where the survival was significantly shorter in patients with positive reaction: subsequently 14.52 and 30.65 months (p<0.05). Patients with co-expression of both proteins had significantly lower survival time (p<0.0005). Similar data has been reported from other clinical centers (18). From 1-, 2-and 3-year observation a strong correlation between survivin and VEGF status and survival time was revealed. Statistically significant higher percentage of survival was noted in patients with VEGF-and survivin-negative tumors.
The golden standard in treatment of gastric carcinoma is surgical procedure. Although the procedures are more oncologically radical, the result is still not satisfying and requires additional treatment. The results of presented research suggest a significant role of survivin and VEGF in biology of gastric carcinoma. Nowadays, studies on new targeted therapies focused on those two proteins are in progress. The study of anti-angiogenic therapy is also advanced and various chemicals were applied, e.g. the anti-VEGF receptor antibodies (19) , anti-VEGF antibodies (Bevacizumab) (20) , peptides inhibiting the activity of VEGFR-2, VEGFR tyrosine kinase inhibitors and oligonucleotides hampering the expression of VEGF gene (21) . Research pertaining to pulmonary, breast and colonic cancer as well as melanoma suggests that they significantly reduce the development of the tumor and formation of metastases in lung carcinoma (22) .
It seems that the therapy hampering VEGF and survivin expression is not only efficient but also has minimal toxic effect on the healthy tissues. This insignificant toxicity may be connected with lower expression of survivin in normal cells vs. neoplastic tissue or the time of observation was not long enough for the negative effect to become evident. Potential side effects of anti-survivin therapy may pertain to proliferating cells such as hematopoietic cell, lymphocytes T, endothelial cells lining the gastro-intestinal tract, hepatocytes and neurons. Particularly the action on lymphocytes T seems worrisome as they are the main mean eliminating the neoplastic cells (23) . Other cases of proven side effects embrace bone marrow stem cells, however the toxicity was minimal compared to overall inhibition of survivin in tumor cells (24).
Another opportunity which is provided by the fact that the expression of survivin is different in normal and tumor cells is using it as early marker of carcinogenesis. This kind of research has been conducted in urinary bladder and oral malignancies and in the latter elevated level of survivin was detected even in precancerous lesions (25, 26) . Similar data indicated increase in survivin expression also in colonic and breast adenomas and Bowen disease which suggests that expression of survivin may be present during malignant transformation or be a sign of imbalance in apoptosis and cellular cycle. Summarizing, survivin may be detected in samples of bodily fluids, easily obtained form the patient and may identify not only tumors but lesions with the increased risk of malignant transformation (26, 27) .
Although the results of this and other studies on survivin and VEGF expression/immunostaining with their clinical meanings seem to be interesting, the real value at this stage may only be in addition to other methods. Possible prognostic value of both proteins may be promising nevertheless further studies are required to assess the true usefulness in the clinical practice.
